Earnings ·
MDxHealth reports Q3 revenue of $22.7M, suspends full-year guidance
MDXHMDxHealth SA
MDxHealth announced preliminary third-quarter 2026 revenue from continuing operations of approximately $22.7 million, matching the prior-year period. The company suspended its full-year 2026 revenue guidance of $110–115 million due to unexpected sales force turnover and aggressive recruiting by competitors following the discontinuation of Resolve mdx. Third-quarter tissue-based test volume decreased 11% to 11,232, while liquid-based Exo mdx volume rose to 11,792 from 4,600 in the prior year. Cash and cash equivalents stood at $31.7 million as of September 30, 2026. MDxHealth is a precision diagnostics company providing molecular tests for prostate cancer and urologic diseases.